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Abstract
The objective of this study was to determine the comparative pharmacodynamics of four different 
carbapenems in combination with polymyxin B (PMB) against carbapenem-resistant 
Acinetobacter baumannii isolates using time–kill experiments at two different inocula. Two A. 
baumannii strains (03-149-1 and N16870) with carbapenem minimum inhibitory concentrations 
(MICs) ranging from 8 to 64 mg/L were investigated in 48-h time–kill experiments using starting 
inocula of 106 CFU/mL and 108 CFU/mL. Concentration arrays of ertapenem, doripenem, 
meropenem and imipenem at 0.25×, 0.5×, 1×, 1.5× and 2× published maximum serum 
concentration (Cmax) values (Cmax concentrations of 12, 21, 48 and 60 mg/L, respectively) were 
investigated in the presence of 1.5 mg/L PMB. Use of carbapenems without PMB resulted in 
drastic re-growth. All carbapenem combinations were able to achieve a ≥3 log10 CFU/mL 
reduction by 4 h against both strains at 106 CFU/mL, whereas maximum reductions against strain 
03-149-1 at 108 CFU/mL were 1.0, 3.2, 2.2 and 3.3 log10 CFU/mL for ertapenem, doripenem, 
meropenem and imipenem, respectively. None of the combinations were capable of reducing 108 
CFU/mL of N16870 by ≥2 log10 CFU/mL. Ertapenem combinations consistently displayed the 
least activity, whereas doripenem, meropenem and imipenem combinations had similar activities 
that were poorly predicted by carbapenem MICs. As doripenem, meropenem, or imipenem 
displayed similar pharmacodyanmics in combination, the decision of which carbapenem to use in 
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combination with PMB may be based on toxicodynamic profiles if drastic discordance in MICs is 
not present.
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1. Introduction
Acinetobacter baumannii is an invasive, opportunistic, Gram-negative pathogen responsible 
for an alarming rate of morbidity and mortality in the intensive care population [1]. 
Historically, carbapenems have been the most reliable treatment option for serious 
nosocomial A. baumannii infections. However, identification of the ideal carbapenem for 
combatting multidrug-resistant A. baumannii has been confounded by conflicting reports of 
minimum inhibitory concentration (MIC) testing and in vitro kill assessments. Whilst 
ertapenem reportedly possesses the least intrinsic activity [2], opposing studies have 
suggested that either doripenem [2], meropenem [3] or imipenem [4] is the most active 
against multidrug-resistant A. baumannii. Unfortunately, acquisition of carbapenem 
resistance mechanisms has further obscured the ideal treatment of A. baumannii.
To counter the increasing prevalence of carbapenem-resistant A. baumannii, clinicians are 
now forced to utilise a polymyxin [colistin or polymyxin B (PMB)] as a drug of last resort 
[5]. However, the emergence of colistin heteroresistance and the increasing frequency of 
polymyxin resistance have precipitated the search for polymyxin combinations that elicit 
greater bacterial killing than is possible with a polymyxin alone [6]. Enhanced activity 
against A. baumannii has been observed when a polymyxin is paired with a carbapenem in 
vitro [7], and successful use of carbapenem/polymyxin combinations has been reported 
clinically [8]. Although a meta-analysis of in vitro carbapenem/polymyxin killing identified 
meropenem and doripenem as the most likely candidates for enhancing polymyxin activity, 
the study results were based on rates of synergy and did not examine the rate and extent of 
killing for each combination [9]. It is also unknown whether the density of the A. baumannii 
inoculum influences selection of the optimal carbapenem. In the present study, we sought to 
characterise the comparative pharmacodynamics of each carbapenem in combination with 
PMB against carbapenem-resistant A. baumannii utilising time–kill experiments conducted 
at two different starting inocula.
2. Materials and methods
Two polymyxin-susceptible A. baumannii strains (N16870 and 03-149-1) were utilised in 
this study. Time–kill experiments were conducted over 48 h at starting inocula of 106 
CFU/mL and 108 CFU/mL in cation-adjusted Mueller–Hinton broth as detailed previously 
[10]. Solutions of ertapenem, doripenem, meropenem and imipenem (Sigma Chemical Co., 
St Louis, MO) were freshly prepared on the day of each experiment. An array of five 
antibiotic concentrations was prepared for each carbapenem. The highest unbound 
maximum serum concentration (Cmax) resulting from the largest clinical dose reported in the 
package insert of each carbapenem was used to standardise the concentration of each agent 
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to clinically achievable levels [11–14]. The other four concentrations used in the arrays 
corresponded to 0.25×, 0.5×, 1.5× and 2× the chosen Cmax value. The following carbapenem 
concentrations were investigated: ertapenem at 3, 6, 12, 18 and 24 mg/L; doripenem at 5.25, 
10.5, 21, 31.5 and 42 mg/L; meropenem at 12, 24, 48, 72 and 96 mg/L; and imipenem at 15, 
30, 60, 90 and 120 mg/L. Bactericidal activity was defined as a ≥3 log10 CFU/mL reduction 
within 24 h.
Carbapenem arrays were investigated in the presence of 1.5 mg/L PMB (Sigma Chemical 
Co.) to approximate the average free steady-state plasma concentration (Css) of PMB 
achieved by a 1.5 mg/kg every 12 h regimen proposed by Sandri et al [15]. PMB alone and 
the highest investigational carbapenem concentration alone served to control for the 
independent activity of each agent. Reaction vessels were incubated in a 37 °C water-bath 
with constant shaking and samples were collected at 0, 1, 2, 4, 8, 24, 26, 28, 32 and 48 h, 
were serially diluted with saline and were plated onto Mueller–Hinton agar. MIC testing was 
performed on 03-149-1 and N16870 in quadruplicate following Clinical and Laboratory 
Standards Institute (CLSI) guidelines M07-A10. Although both strains were susceptible to 
PMB (MIC of 0.5 mg/L for both isolates), the respective carbapenem MICs for 03-149-1 
and N16870 were both 64 mg/L for ertapenem, 32 mg/L and 16 mg/L for doripenem, 64 
mg/L and 16 mg/L for meropenem, and 32 mg/L and 8 mg/L for imipenem.
The log ratio change (Eq. 1) was calculated for the ertapenem, doripenem, meropenem and 
imipenem combinations that achieved the greatest A. baumannii killing [16]. As the log ratio 
change is only sensitive to A. baumannii counts at a discrete time and does not reflect the 
bacterial burden throughout the 48-h experiments, the log ratio area (Eq. 2) was also 
calculated for the most active carbapenem combinations to provide insight into antimicrobial 
activity achieved over the course of the entire experiment. The log ratio change and the log 
ratio area of each carbapenem combination were compared with one another for both A. 
baumannii strains at both starting inocula to determine differences in the rate and extent of 
killing for each combination.
(1)
(2)
where AUCFU is the area under the CFU–time curve.
3. Results
The results of the time–kill experiments at the 106 CFU/mL inoculum are displayed in Fig. 
1. For strain 03-149-1, all four carbapenems were able to achieve a ≥3 log10 CFU/mL 
reduction by 6 h [Fig. 1(A1–A4)]. Ertapenem combinations displayed the least activity, with 
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bacterial counts that began to recover by 8 h independent of the ertapenem concentration 
used in the combination (mean standard deviation 0.4 log10 CFU/mL). The majority of 
doripenem combinations also resulted in regrowth by 8 h, with a maximum reduction of 3.8 
log10 CFU/mL by 8 h. Meropenem and imipenem combinations achieved sustained killing 
up to 8 h, with maximum reductions at 8 h of 4.5 log10 CFU/mL for both carbapenem 
combinations.
Despite relatively similar MICs to strain 03-149-1, carbapenem combinations achieved more 
drastic killing against 106 CFU/mL of N16870 [Fig. 1(B1–B4)]. Ertapenem combinations 
again displayed the least activity, with all five combinations ascending above 107 CFU/mL 
by 32 h. Both meropenem and imipenem alone were capable of sustained killing against 
N16870, albeit more slowly than in combination treatments, whilst doripenem alone regrew 
by 24 h. Doripenem, meropenem and imipenem combinations all displayed sustained killing 
that was dependent on the carbapenem concentration, with maximum reductions at the limit 
of detection (100 CFU/mL) for all three combinations. The lowest doripenem concentration 
of 5.25 mg/L was also the only concentration that resulted in complete regrowth by 48 h 
when in combination with PMB.
In contrast to the bactericidal activity observed at 106 CFU/mL, the majority of carbapenem 
combinations were unable to substantially reduce the 108 CFU/mL A. baumannii burden by 
24 h (Fig. 2). The reductions in 03-149-1 counts at 8 h achieved by the highest concentration 
combinations were 1.0, 3.2, 2.2 and 3.3 log10 CFU/mL for ertapenem, doripenem, 
meropenem and imipenem, respectively [Fig. 2(A1–A4)]. The highest concentration of 
doripenem (42 mg/L) in combination with PMB resulted in the most sustained killing, with a 
3.2 log10 CFU/mL reduction of 03-149-1 at 8 h that was maintained until 26 h.
Although killing of N16870 was more drastic compared with 03-149-1 at 106 CFU/mL, at 
the 108 CFU/mL inoculum N16870 was more tolerant to the carbapenem and PMB 
combinations [Fig. 2(B1–B4)]. At 8 h, maximum reductions achieved by carbapenem 
combinations were 0.5, 1.6, 1.2 and 1.1 log10 CFU/mL for ertapenem, doripenem, 
meropenem and imipenem, respectively. The only combination capable of sustained killing 
was 96 mg/L meropenem in combination with PMB, which resulted in a nadir of 6.5 log10 
CFU/mL at 32 h followed by subsequent regrowth. PMB alone was unable to achieve 
sustained killing against either strain at either inoculum.
A comparison of the maximum activities displayed by all four carbapenem combinations 
expressed as either the log ratio area or log ratio change at 48 h is summarised in Fig. 3. 
After 48 h of antimicrobial exposure, none of the carbapenem combinations achieved 
substantial reductions in bacterial counts against strain 03-149-1 at either inoculum [Fig. 
3(A1)]; however, the log ratio areas of doripenem, meropenem and imipenem combinations 
were ≥1.1 lower than the ertapenem combination at the 106 CFU/mL inoculum [Fig. 3(A2)]. 
Against the N16870 strain, both the log ratio change and the log ratio areas of all four 
carbapenem combinations were comparable at the 108 CFU/mL inoculum, whereas the log 
ratio change of the most active ertapenem combination was ≥5.2 higher than the other 
carbapenem combinations at 106 CFU/mL [Fig. 3(B1)]. Similarly, ertapenem with PMB 
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achieved a log ratio area of −2.0 that was ≥2.7 higher than the other carbapenem 
combinations at 106 CFU/mL [Fig. 3(B2)].
4. Discussion
The ability of A. baumannii to acquire resistance mechanisms to commonly used antibiotics 
has made the pathogen particularly troubling in the nosocomial environment [1]. Here we 
sought to characterise the pharmacodynamics of four different carbapenems in combination 
with PMB at two different inocula to better understand the killing of antimicrobial 
combinations against carbapenem-resistant A. baumannii. Regardless of the inoculum, a 
PMB concentration of 1.5 mg/L was unable to achieve sustained killing for up to 48 h 
despite PMB MICs of 0.5 mg/L. When carbapenems were added to PMB, killing drastically 
improved, but was more pronounced at the 106 CFU/mL inoculum. The utility of colistin in 
combination with meropenem is currently being investigated in two clinical trials 
(NCT01732250 and NCT01597973) that will help illuminate the clinical utility of 
polymyxin combinations.
A previous hollow-fibre infection analysis of PMB alone against A. baumannii with 
susceptible PMB MICs also failed to eradicate the pathogen in vitro [17]. Despite rapid 
initial killing, polymyxin-resistant subpopulations amplified by over 5 log10 CFU/mL within 
24 h of PMB exposure to allow for continued growth in the presence of PMB. In the present 
study, the rapid initial killing by PMB alone at the 106 CFU/mL inoculum was likely 
followed by a similar amplification of polymyxin-resistant subpopulations. When the A. 
baumannii was exposed to PMB and a carbapenem, PMB likely permeabilised the outer 
membrane of the bacterial cells and increased the accessibility of penicillin-binding proteins 
for the β-lactams [18].
Using the measures of log ratio area and log ratio change, doripenem, meropenem and 
imipenem combinations resulted in similar killing profiles against both A. baumannii strains. 
However, the use of only two A. baumannii isolates limits our ability to generalise the 
findings to other A. baumannii clinical strains. Similar to how ertapenem was previously 
identified as the least active agent against carbapenem-susceptible A. baumannii [2], 
ertapenem in combination with PMB displayed the least killing against both strains 
regardless of the inoculum. Interest in the utility of ertapenem against carbapenem-resistant 
Gram-negative organisms has risen following the reported use of ertapenem combination 
therapies targeted at carbapenem-resistant Klebsiella pneumoniae [19]. Although the results 
of the current investigation suggest that ertapenem may offer unfavourable 
pharmacodynamics in combination with PMB against carbapenem-resistant A. baumannii, 
dynamic in vitro models are needed to fully define the combinatorial pharmacodynamics of 
such a combination.
Not only were similar killing profiles observed for doripenem, meropenem and imipenem, 
but a large inoculum effect was consistently observed among the three carbapenem 
combinations as well. Killing was the most drastic against N16870 in both the log ratio area 
and log ratio change analyses at a 106 CFU/mL inoculum, yet the most substantial killing at 
a 108 CFU/mL inoculum was achieved against strain 03-149-2. The magnitude of the 
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inoculum effect in carbapenem-resistant A. baumannii is therefore difficult to predict, as the 
attenuation in antimicrobial activity varied markedly between both strains. Given the similar 
declines in bacterial killing as the inoculum increased from 106 CFU/mL to 108 CFU/mL, 
the bacterial burden of A. baumannii may not influence whether doripenem, meropenem or 
imipenem is the ideal agent for polymyxin combination therapy.
Although both A. baumannii strains possessed different carbapenem MICs that varied by 
multiple dilutions, the MIC of each carbapenem was not able to fully predict the activity of 
each combination. When used in monotherapy, the prevailing dogma for β-lactams asserts 
that obtaining a sufficient %T>MIC (percentage of the dosing interval that the plasma level 
exceeds the MIC of the causative pathogen) is necessary for bactericidal activity [20]. 
However, the ability of PMB to perturb the integrity of both the outer and inner membranes 
of A. baumannii and increase carbapenem permeability is not accounted for by simply using 
the MIC of a carbapenem to predict the activity of combination treatment [18]. At a 106 
CFU/mL inoculum, doripenem, meropenem and imipenem combinations utilising 
carbapenem concentrations below the MIC achieved bactericidal activity (0%T>MIC), 
suggesting that a concentration dependence exists during combination therapy that is not 
entirely accounted for by the %T>MIC metric.
A significant limitation of the current study is the use of static time–kill experiments that do 
not simulate the dynamic pharmacokinetics of carbapenems and PMB. Although doripenem, 
meropenem and imipenem all share a similar half-life of ca. 1 h in healthy volunteers 
[11,13,14], ertapenem possesses a half-life of 4 h that may confer additional bacterial killing 
in comparison with the other carbapenems [12]. Further work with dynamic in vitro models 
or in vivo animal models is needed to fully define the combinatorial pharmacodynamics of 
carbapenems in combination with PMB.
5. Conclusions
During A. baumannii time–kill experiments, ertapenem was the least active carbapenem in 
combination with PMB, whilst doripenem, meropenem and imipenem combinations 
displayed slight differences in their activities that were influenced by the A. baumannii 
strain and bacterial burden. Individual carbapenem MICs were also poorly predictive of how 
each carbapenem performed when in combination with PMB. Given the similar activities of 
doripenem, meropenem and imipenem when paired with PMB, the decision of which 
carbapenem to use for combination treatment may be driven by the toxicity profiles of each 
carbapenem if MICs are similar. Further investigations that use dynamic models to 
completely simulate the pharmacokinetics of carbapenems in combination with PMB are 
needed to better translate the findings into the clinical setting.
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Time–kill experiments of (A) strain 03-149-1 and (B) strain N16870 at a starting inoculum 
of 106 CFU/mL. Five concentrations of ertapenem (A1/B1), doripenem (A2/B2), 
meropenem (A3/B3) and imipenem (A4/B4) were investigated with 1.5 mg/L polymyxin B 
(PolyB). The highest concentrations of each carbapenem alone and PolyB alone were 
investigated separately to account for the independent activity of each agent.
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Time–kill experiments of (A) strain 03-149-1 and (B) strain N16870 at a starting inoculum 
of 108 CFU/mL. Five concentrations of ertapenem (A1/B1), doripenem (A2/B2), 
meropenem (A3/B3) and imipenem (A4/B4) were investigated with 1.5 mg/L polymyxin B 
(PolyB). The highest concentrations of each carbapenem alone and PolyB alone were 
investigated separately to account for the independent activity of each agent.
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(A) Log ratio change and (B) log ratio area after 48 h of exposure to the most active 
combinations of polymyxin B with either ertapenem, meropenem, imipenem or doripenem 
for strain 03-149-1 (A1/B1) and strain N16870 (A2/B2) at two different initial inocula.
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